Maryland
DEPARTMENT OF HEALTH

Maryland Situation Update on Coronavirus Disease (COVID-19) for BHA

Maryland Department of Health

Infectious Disease Epidemiology and Outbreak Response Bureau

November 12, 2021

Call Agenda

- Epi summary
- Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity
- Pediatric Vaccine Update
- Q and A

https://covidlink.maryland.gov/content/vaccine/govax/

GoVAX

Let's end COVID, Maryland.

Maryland DEPARTMENT OF HEALTH

Worldwide: COVID-19



Maryland DEPARTMENT OF HEALTH

Source: https://covid19.who.int/ accessed 11/12/21

Worldwide: COVID-19

Source: https://covid19.who.int/ accessed 11/12/21



US Case Counts and Rates



https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
11/12/2021

Maryland
DEPARTMENT OF HEALTH

Number of Cases Reported in the USA, by Day



Maryland
DEPARTMENT OF HEALTH

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases Updated 11/12/2021

Community Transmission

https://covid.cdc.gov/covid-data-tracker/#county-view
11/12/2021



High Substantial Moderate Low No Data

Maryland
DEPARTMENT OF HEALTH

http://health.maryland.gov/coronavirus

Data current as of 11/12/2021

Maryland: COVID-19 Cases

- Cases: 569,823
  - 909 new
- Deaths: 10,798
  - 10 new
- Hospitalizations: 51,276
  Current: 507 (Up 2)
- Case rate: 12.4 per 100,000
- Percent Positivity: 2.80%



Maryland
DEPARTMENT OF HEALTH

Maryland: COVID-19

Source: https://coronavirus.maryland.gov/, accessed 11/12/21



Maryland
DEPARTMENT OF HEALTH

Maryland: COVID-19



Source: https://coronavirus.maryland.gov/, accessed 11/12/21

Maryland
DEPARTMENT OF HEALTH

Maryland: COVID-19



11/12/21: **12.4** per 100k

Low: 6/24/21 at 0.90 per 100K

High: 1/12/21 at **53.39** per 100k

Source: https://coronavirus.maryland.gov/, accessed 11/12/21

Maryland DEPARTMENT OF HEALTH

Maryland: COVID-19



Source: https://coronavirus.maryland.gov/, accessed 11/12/21

Maryland
DEPARTMENT OF HEALTH

Maryland: COVID-19



Source: https://coronavirus.maryland.gov/, accessed 11/12/21

Maryland DEPARTMENT OF HEALTH

US: COVID-19 Vaccinations

Total Vaccine Doses

Delivered 541,361,525

Administered 434,486,889

Learn more about the distribution of vaccines.

194.4M

People fully vaccinated

26.1M

People received a booster dose**

At Least One Dose | Fully Vaccinated | Booster Dose

Fully Vaccinated* People	Count	Percent of US Population
Total	194,382,921	58.5%
Population ≥ 12 Years of Age	194,246,191	68.5%
Population ≥ 18 Years of Age	181,485,362	70.3%
Population ≥ 65 Years of Age	46,990,061	85.8%

***For surveillance purposes, COVID Data Tracker counts people as being "fully vaccinated" if they received two**

Source: https://covid.cdc.gov/covid-data-tracker/#vaccinations accessed 11/12/21

Maryland DEPARTMENT OF HEALTH

Maryland Vaccine Dashboard



https://coronavirus.maryland.gov/#Vaccine accessed 11/12/2021

Maryland
DEPARTMENT OF HEALTH

Percent of age groups with at least one dose



https://coronavirus.maryland.gov/#Vaccine 11/12/2021

DEPARTMENT OF HEALTH

US: Delta Variant

https://covid.cdc.gov/covid-data-tracker/#variant-proportions Accessed 11/12/21



HHS Region 3: 10/31/2021 – 11/6/2021 NOWCAST

Region 3 - Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia

WHO label	Lineage #	US Class	%Total	95%PI
Delta	B.1.617.2	VOC	99.9%	99.9-100.0%
	AY.1	VOC	0.0%	0.0-0.1%
	AY.2	VOC	0.0%	0.0-0.0%
Other	Other*		0.0%	0.0-0.0%

* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.
** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
# AY.3-AY.47 and their sublineages are aggregated with B.1.617.2.

Maryland DEPARTMENT OF HEALTH

Maryland Influenza Dashboard

https://health.maryland.gov/phpa/influenza/Pages/flu-dashboard.aspx
accessed 11/9/21

ILI Activity:

During the week ending October 30,2021, overall influenza-like illness (ILI) activity in Maryland was Minimal.

Activity Indicators:

The proportion of visits to Maryland sentinel outpatient providers that were for ILI was 2.0%, which is AT the Maryland baseline of 2.0%.

The proportion of visits to the Maryland Emergency Departments that were for ILI was 2.3%.

The proportion of the Maryland Resident Influenza Tracking Survey (MRITS) respondents who reported ILI was 0 (0.0%).

Maryland sentinel clinical laboratories reported testing 3,371 specimens for influenza and 62 (1.8%) tested positive for influenza virus. Of those testing positive, 34 (55%) were influenza Type A and 28 (45%) were influenza Type B.*

The Maryland Department of Health Laboratories Administration tested 1,026 specimens for influenza and one (0.1%) tested positive for influenza A(H3).

Two RSV outbreaks were reported to the Maryland local health departments this week.

* Flu antigen test positive, not confirmed by PCR testing.

Severity Indicators:

No influenza-associated hospitalizations were reported for the week ending October 30, 2021.

No influenza-associated adult deaths were reported for the week ending October 30, 2021.

Maryland
DEPARTMENT OF HEALTH

Maryland Influenza Dashboard

https://health.maryland.gov/phpa/influenza/Pages/flu-dashboard.aspx
accessed 11/10/21



Maryland
DEPARTMENT OF HEALTH

Maryland Influenza Dashboard

https://health.maryland.gov/phpa/influenza/Pages/flu-dashboard.aspx
accessed 10/27/21



Influenza Associated Hospitalization by Age Group 2021-2022 Influenza Season

Hospitalizations by Age Group (Years)	This Week Count	This Week Percent	Last Week Count	Last Week Percent
0-4	0	0%	0	0%
5-24	1	100%	1	0%
25-49	0	0%	1	0%
50-64	0	0%	1	0%
65+	0	0%	0	0%

Maryland DEPARTMENT OF HEALTH

MMWR

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Maryland
DEPARTMENT OF HEALTH

Immunity in Patients Hospitalized for COVID-19

- Previous infection with SARS-CoV-2 or COVID-19 vaccination can provide immunity and protection against subsequent SARS-CoV-2 infection and illness
- To compare the early protection against COVID-19 conferred by SARS-CoV-2 infection and by receipt of mRNA COVID-19 vaccines (i.e., 90–179 days after infection or vaccination), the VISION Network collected data from 187 hospitals across nine states during January–September 2021

https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm?s_cid=mm7044e1_w

Results and Conclusions

- Laboratory-confirmed SARS-CoV-2 infection was identified among 324 (5.1%) of 6,328 fully vaccinated persons and among 89 of 1,020 (8.7%) unvaccinated, previously infected persons
- The odds of laboratory-confirmed COVID-19 were higher among previously infected, unvaccinated patients than among fully vaccinated patients (aOR = 5.49; 95% CI = 2.75–10.99)
- Vaccine-induced immunity was more protective than infection-induced immunity against laboratory-confirmed COVID-19, including during a period of Delta variant predominance.
- All eligible persons should be vaccinated against COVID-19 as soon as possible, including unvaccinated persons previously infected with SARS-CoV-2.

https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e1.htm?s_cid=mm7044e1_w

Pediatric Vaccine Update

Maryland
DEPARTMENT OF HEALTH

Pediatric COVID-19 Vaccine for 5-11 year olds

- Pfizer-BioNTech is now authorized for all children 5-11 years
- Children ages 5 through 11 years receive one-third of the adult dose of Pfizer-BioNTech COVID-19 Vaccine.
  - Note the 5-11 year old vaccine formulation is different than the vaccine for ages 12 and up- Children under 12 may not be vaccinated with a smaller dose of the adult formulation
- Smaller needles, designed specifically for children, are used for children ages 5 through11 years.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html

Recommendations for Pediatric Populations

- All children ages 5 to 11 are eligible for COVID-19 vaccine
- Available safety and immunogenicity data for Pfizer-BioNTech COVID-19 vaccines in children and adolescents are similar to those seen in young adults
- Children should receive the age-appropriate vaccine formulation regardless of their size or weight.
- Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2

Maryland DEPARTMENT OF HEALTH

https://www.cdc.gov/vaccines/covid-19/planning/children.html#covid19-vax-recommendations

Pediatric Vaccination dosing

TABLE. COVID-19 vaccines approved or authorized by the Food and Drug Administration for persons aged <18 years — United States, November 2021*

Return

Age group at vaccination, yrs	Vaccine manufacturer	Vial cap color	Concentration of mRNA per dose	Injection volume	Diluent† volume	Doses per vial
5–11	Pfizer-BioNTech	Orange	10 μg	0.2 mL	1.3 mL	10
12–17	Pfizer-BioNTech	Purple	30 μg	0.3 mL	1.8 mL	6

https://www.cdc.gov/mmwr/volumes/70/wr/mm7045e1.htm?s_cid=mm7045e1_w#T1_down

Pfizer-BioNTech COVID-19 Vaccines

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	Dilute Prior to Use	*Dilute Prior to Use*
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks

Q: Can the current adult/adolescent formulation (purple cap) be used to vaccinate children 5 to <12 years old once the vaccine is authorized for this age group?

A: No. For children under 12 years of age, you cannot use the current formulation and will need to use the future pediatric (orange cap) formulation.

Purple Cap – Adult/Adolescent: Authorized only for ages 12 years and older

Orange Cap – Pediatric: Future authorization for ages 5 to <12 years. A separate vaccine formulation specific for a 10mcg dose will be introduced.

***NOTE:** Use of the current adult/adolescent formulation (purple cap) to prepare doses for children 5 to <12 years would result in an injection volume for the 10mcg dose of 0.1mL, which is both generally considered too small for typical IM injections and has not been studied.*

**Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS)*

***The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 5 to <12 years old*

https://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Pediatric-Reference-Planning.pdf
11/10/2021

Maryland
DEPARTMENT OF HEALTH

Questions?

mdh.ipcovid@maryland.gov

Maryland
DEPARTMENT OF HEALTH